Axsome therapeutics, inc. (AXSM)
CashFlow / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15
Cash flows from operating activities
Net loss

-32,484

-24,806

-19,135

-13,762

-10,640

-9,597

-8,281

-8,280

-4,805

-7,430

-6,433

-7,084

-7,995

-7,328

-7,194

-6,812

-5,865

-3,364

-4,576

-2,129

-2,140

Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation expense

2,133

2,813

1,156

888

1,256

353

392

474

534

536

388

483

663

434

458

482

656

182

360

185

74

Non-cash research and development license expense

7,155

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Amortization of debt discount

177

178

176

187

107

82

88

96

108

117

119

117

115

-

-

-

-

-31

22

35

16

Amortization of debt issuance costs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

2

3

1

Non-cash interest expense

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

156

257

173

111

Change in fair value of warrants

-

-

-

-

-

-102

-15

-1

-2,673

-

-

-

-

-

-

-

-

-

-

-

-

Change in fair value of warrant and embedded derivative liabilities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

14

171

166

-78

Depreciation

5

5

9

11

11

12

13

11

11

11

10

10

10

9

5

3

2

1

1

0

0

Changes in operating assets and liabilities:
Prepaid expenses and other current assets

-103

-181

-220

-319

-111

522

-464

66

-157

532

-96

-336

-201

513

-297

177

-9

652

91

191

-64

Other assets

3

-29

0

67

-10

-5

0

2

-73

68

0

0

6

53

1

0

30

-

-

-

-

Accounts payable

1,248

1,495

3,310

2,702

-253

-480

992

-699

439

492

-1,095

-702

659

213

832

1,204

-61

1,148

-330

-167

483

Accrued expenses and other current liabilities

-1,609

2,536

3,635

1,038

-103

455

434

800

-526

-64

466

-258

-285

-47

799

-14

1,343

219

181

148

150

Net cash used in operating activities

-23,273

-17,567

-10,626

-8,681

-9,499

-9,793

-5,912

-7,667

-6,680

-6,291

-6,447

-7,096

-6,636

-7,216

-4,802

-5,314

-3,947

-2,250

-1,922

-2,106

-1,158

Cash flows from investing activities
Purchases of equipment

9

-

-

-

-

0

8

9

14

0

3

3

2

6

76

11

10

4

4

1

10

Net cash used in investing activities

-9

-

-

-

-

0

-8

-9

-14

-0

-3

-3

-2

-6

-76

-11

-10

-4

-4

-1

-10

Cash flows from financing activities
Deferred financing fees

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-33

141

13

Procceds from issuance of common stock upon financing, net

-

193,778

0

19,471

24,983

8,921

1,590

2,229

139

8,896

0

-8

14,790

-

-

-

-

-

-

-

-

Proceeds from issuance of common stock upon exercise of options

629

44

483

205

410

-

-

-

-

7

89

18

201

-

-

-

-

-

-

-

-

Proceeds from issuance of convertible notes

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

99

7,027

255

Proceeds from issuance of term loan

-

0

0

0

20,000

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Repayment of principal on term loan

-

0

0

0

7,238

833

833

833

833

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds issuance of common stock upon exercise of warrants

-

-

-

-

-

-

-

-

-

13

40

65

49

-

-

-

-

-

-

-

-

Net cash (used in) provided by financing activities

629

193,892

518

19,821

38,154

8,541

789

1,395

-693

8,638

129

74

15,040

-

-

-

-

45,670

133

6,832

241

Net (decrease) increase in cash

-22,652

176,324

-10,111

11,128

28,655

-1,252

-5,130

-6,281

-7,388

2,347

-6,321

-7,025

8,401

2,730

-4,863

-5,326

-3,958

43,415

-1,793

4,723

-927

Supplemental disclosures of cash flow information:
Interest paid

379

308

383

379

216

186

182

195

206

-

-

-

-

-

-

-

-

-

-

-

-

Supplemental disclosures of non-cash financing activity:
Issuance of warrants in connection with debt financing

-

0

0

-39

426

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Warrants issued for debt financing and offering costs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

19